Form 4: Jaguar Health Director Siegel Receives Equity Grants

Jaguar Health, Inc. Director Jonathan B. Siegel was granted 7,377 restricted stock units and options to purchase 7,377 shares of common stock on December 11, 2025.

Summary

• Jonathan B. Siegel, a Director of Jaguar Health, Inc. (JAGX), reported the acquisition of equity securities.
• On December 11, 2025, Siegel was granted 7,377 shares of common stock in the form of Restricted Stock Units (RSUs) at a price of $0 per share.
• Following this transaction, Siegel beneficially owns 7,423 shares of common stock.
• Also on December 11, 2025, Siegel was granted stock options to acquire 7,377 shares of common stock with an exercise price of $1.44 per share.
• Both the RSUs and stock options were granted pursuant to the issuer's 2014 Stock Incentive Plan and approved by the board of directors on December 11, 2025.
• The RSUs are scheduled to vest on December 11, 2026.
• The stock options will vest ratably on a monthly basis over 12 months from the grant date, contingent on Siegel's continued service on the board of directors of Jaguar Health, Inc. and Napo Therapeutics, S.p.A., a subsidiary.
• The options have an expiration date of December 11, 2035.
• The company previously effected a 60-for-1 reverse stock split on May 23, 2024, and a 25-for-1 reverse stock split on March 24, 2025.

Sentiment

Score: 6

Explanation: The filing reports routine director compensation through equity grants, which is generally a neutral to slightly positive event as it aligns director interests with shareholders. There are no immediate negative implications from the grants themselves, though the historical reverse stock splits mentioned are a contextual concern.

Positives

• The equity grants align the interests of Director Jonathan B. Siegel with those of shareholders, as his compensation is tied to the company's future stock performance.
• The grants are part of a standard compensation plan (2014 Stock Incentive Plan), indicating a structured approach to executive and director incentives.

Risks

• The vesting of both the restricted stock units and stock options is contingent on Jonathan B. Siegel's continued service on the board, meaning the benefits are not guaranteed if his service ceases.
• The company has undergone two significant reverse stock splits (60-for-1 on May 23, 2024, and 25-for-1 on March 24, 2025), which often indicate historical challenges with stock price performance and can be a concern for investors regarding future share value.

Future Outlook

The future outlook for Jonathan B. Siegel's equity holdings is tied to the vesting schedules of the granted RSUs and stock options, which extend through December 2026 for RSUs and monthly over 12 months from December 2025 for options, contingent on his continued board service. The options have a long-term expiration date of December 2035, indicating a long-term incentive horizon.

Industry Context

The granting of restricted stock units and stock options to a director is a common practice in the biotechnology and pharmaceutical industry, as well as other sectors, to incentivize long-term commitment and align management interests with shareholder value. This type of compensation is a standard component of corporate governance and executive remuneration packages.

Comparison to Industry Standards

• The use of restricted stock units and stock options for director compensation is a widely accepted practice across industries, including biotechnology, aligning with global benchmarks for executive and board remuneration.
• The vesting schedules (one year for RSUs, monthly over 12 months for options) are typical for such grants, designed to retain talent and encourage sustained performance, comparable to practices at companies like Pfizer or Moderna for their non-executive directors.
• The grant price of $0 for RSUs is standard, representing a direct equity award, while the exercise price of $1.44 for options reflects the market price at the time of grant, a common feature in incentive plans.

Corporate Governance

Related Party Transactions

• The equity grants to Jonathan B. Siegel, a Director of Jaguar Health, Inc., constitute a related party transaction as they involve compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The grants represent potential future dilution if options are exercised and RSUs vest, but also aim to align the director's interests with long-term shareholder value creation.
• Director (Jonathan B. Siegel): Receives significant equity-based compensation, incentivizing continued service and performance.

Next Steps

• The restricted stock units are scheduled to vest on December 11, 2026, at which point the shares will be delivered to the reporting person.
• The stock options will vest ratably on a monthly basis over 12 months from December 11, 2025, provided Jonathan B. Siegel continues his service on the boards of Jaguar Health, Inc. and Napo Therapeutics, S.p.A.

Key Dates

Keywords

Jaguar Health, JAGX, Form 4, insider transaction, equity grant, restricted stock units, stock options, director compensation, stock incentive plan, reverse stock split